{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:04:28Z","timestamp":1791057868805,"version":"4.1.0"},"reference-count":119,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over conventional chemotherapies, the drug exhibits off-target effects. An unanticipated side effect of imatinib therapy is hypophosphatemia and hypocalcemia, which in part has been attributed to drug-mediated changes to renal and gastrointestinal handling of phosphate and calcium. However, emerging data suggest that imatinib also targets cells of the skeleton, stimulating the retention and sequestration of calcium and phosphate to bone, leading to decreased circulating levels of these minerals. The aim of this review is to highlight our current understanding of the mechanisms surrounding the effects of imatinib on the skeleton. In particular, it examines recent studies suggesting that imatinib has direct effects on bone-resorbing osteoclasts and bone-forming osteoblasts through inhibition of c-fms, c-kit, carbonic anhydrase II, and the platelet-derived growth factor receptor. The potential application of imatinib in the treatment of cancer-induced osteolysis will also be discussed.<\/jats:p>","DOI":"10.1182\/blood-2009-08-237404","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T03:40:46Z","timestamp":1257392446000},"page":"766-774","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["Dysregulation of bone remodeling by imatinib mesylate"],"prefix":"10.1182","volume":"115","author":[{"given":"Kate","family":"Vandyke","sequence":"first","affiliation":[{"name":"Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide;"},{"name":"School of Medicine, University of Adelaide, Adelaide; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fitter","sequence":"additional","affiliation":[{"name":"Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Dewar","sequence":"additional","affiliation":[{"name":"Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide; and"},{"name":"Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C. W.","family":"Zannettino","sequence":"additional","affiliation":[{"name":"Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide;"},{"name":"School of Medicine, University of Adelaide, Adelaide; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111723195598400_B1","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"issue":"14","key":"2019111723195598400_B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111723195598400_B3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"8","key":"2019111723195598400_B4","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571.","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111723195598400_B5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2019111723195598400_B6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2019111723195598400_B7","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111723195598400_B8","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"2019111723195598400_B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6807-9-7","article-title":"The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).","volume":"9","author":"Winger","year":"2009","journal-title":"BMC Struct Biol"},{"issue":"15","key":"2019111723195598400_B10","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.bmcl.2009.06.002","article-title":"The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian \u03b1-carbonic anhydrase isoforms.","volume":"19","author":"Parkkila","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"2019111723195598400_B11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111723195598400_B12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate.","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111723195598400_B13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMc061565","article-title":"Imatinib and altered bone and mineral metabolism.","volume":"355","author":"Owen","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111723195598400_B14","first-page":"628","article-title":"Imatinib and altered bone and mineral metabolism.","volume":"355","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111723195598400_B15","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111723195598400_B16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.","volume":"94","author":"O'Sullivan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019111723195598400_B17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients.","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111723195598400_B18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"issue":"23","key":"2019111723195598400_B19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111723195598400_B20","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.ejca.2006.03.029","article-title":"Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).","volume":"42","author":"Van Glabbeke","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"2019111723195598400_B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2019111723195598400_B22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111723195598400_B23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","article-title":"Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.","volume":"51","author":"Fran\u00e7ois","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2019111723195598400_B24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pop.2008.01.007","article-title":"Disorders involving calcium, phosphorus, and magnesium.","volume":"35","author":"Moe","year":"2008","journal-title":"Prim Care"},{"issue":"6","key":"2019111723195598400_B25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00003495-200161060-00010","article-title":"Zoledronic acid.","volume":"61","author":"Cheer","year":"2001","journal-title":"Drugs"},{"issue":"7435","key":"2019111723195598400_B26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.328.7435.335","article-title":"Severe hypocalcaemia after being given intravenous bisphosphonate.","volume":"328","author":"Peter","year":"2004","journal-title":"BMJ"},{"issue":"6","key":"2019111723195598400_B27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates.","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111723195598400_B28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.","volume":"93","author":"J\u00f6nsson","year":"2008","journal-title":"Haematologica"},{"key":"2019111723195598400_B29","first-page":"S189","article-title":"Influence of imatinib on bone remodeling in juvenile mice [abstract].","volume":"23","author":"Boehme","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2019111723195598400_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1100.1100","article-title":"Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure [abstract].","volume":"112","author":"Suttorp","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111723195598400_B31","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL.","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111723195598400_B32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"3","key":"2019111723195598400_B33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/bbrc.1999.0252","article-title":"A new member of tumor necrosis factor ligand family, ODF\/OPGL\/TRANCE\/RANKL, regulates osteoclast differentiation and function.","volume":"256","author":"Takahashi","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2019111723195598400_B34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1242\/dev.120.6.1357","article-title":"Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse.","volume":"120","author":"Cecchini","year":"1994","journal-title":"Development"},{"issue":"10","key":"2019111723195598400_B35","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1172\/JCI119790","article-title":"Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts.","volume":"100","author":"Insogna","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111723195598400_B36","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/endo.141.6.7480","article-title":"Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1.","volume":"141","author":"Grey","year":"2000","journal-title":"Endocrinology"},{"issue":"24","key":"2019111723195598400_B37","doi-asserted-by":"crossref","first-page":"21971","DOI":"10.1074\/jbc.M200434200","article-title":"Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B.","volume":"277","author":"Cappellen","year":"2002","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111723195598400_B38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNF\u03b1 and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase.","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ"},{"issue":"11","key":"2019111723195598400_B39","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease.","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111723195598400_B40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00774-006-0684-1","article-title":"Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA).","volume":"24","author":"Ando","year":"2006","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2019111723195598400_B41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"2019111723195598400_B42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2403071","article-title":"Imatinib inhibits the in vitro development of the monocyte\/macrophage lineage from normal human bone marrow progenitors.","volume":"17","author":"Dewar","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111723195598400_B43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1711.2004.01296.x","article-title":"Imatinib inhibits the functional capacity of cultured human monocytes.","volume":"83","author":"Dewar","year":"2005","journal-title":"Immunol Cell Biol"},{"issue":"11","key":"2019111723195598400_B44","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111723195598400_B45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.0105-2896.2005.00331.x","article-title":"\u03b1v\u03b23 and macrophage colony-stimulating factor: partners in osteoclast biology.","volume":"208","author":"Ross","year":"2005","journal-title":"Immunol Rev"},{"issue":"1","key":"2019111723195598400_B46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.","volume":"25","author":"Taylor","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"2019111723195598400_B47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-05-0359","article-title":"Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.","volume":"5","author":"Guo","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2019111723195598400_B48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/leu.2008.295","article-title":"Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1\/CSF1R signaling abnormalities in the cell line GDM1.","volume":"23","author":"Chase","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111723195598400_B49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2404944","article-title":"Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.","volume":"22","author":"Brownlow","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"2019111723195598400_B50","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.190.12.1741","article-title":"Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor \u03baB (RANK) receptors.","volume":"190","author":"Arai","year":"1999","journal-title":"J Exp Med"},{"issue":"6274","key":"2019111723195598400_B51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene.","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"issue":"2","key":"2019111723195598400_B52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.190.2.293","article-title":"Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption.","volume":"190","author":"Niida","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"2019111723195598400_B53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.V99.1.111","article-title":"Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects.","volume":"99","author":"Dai","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111723195598400_B54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111723195598400_B55","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111723195598400_B56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1091\/mbc.3.3.349","article-title":"Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2.","volume":"3","author":"Huang","year":"1992","journal-title":"Mol Biol Cell"},{"issue":"6","key":"2019111723195598400_B57","first-page":"753","article-title":"Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor.","volume":"7","author":"Gattei","year":"1996","journal-title":"Cell Growth Differ"},{"issue":"12","key":"2019111723195598400_B58","first-page":"480","article-title":"The kit receptor and its ligand, steel factor, as regulators of hemopoiesis.","volume":"3","author":"Broxmeyer","year":"1991","journal-title":"Cancer Cells"},{"issue":"11","key":"2019111723195598400_B59","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jbmr.5650071114","article-title":"Effects of stem cell factor on osteoclast-like cell formation in long-term human marrow cultures.","volume":"7","author":"Demulder","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019111723195598400_B60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0773.1998.tb01429.x","article-title":"Effect of stem cell factor, interleukin-6, nitric oxide and transforming growth factor-beta on the osteoclast differentiation induced by 1 alpha,25-(OH)2D3 in primary murine bone marrow cultures.","volume":"82","author":"Chae","year":"1998","journal-title":"Pharmacol Toxicol"},{"issue":"4","key":"2019111723195598400_B61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1096\/fasebj.11.4.9068618","article-title":"Stem cell factor stimulates chicken osteoclast activity in vitro.","volume":"11","author":"van't Hof","year":"1997","journal-title":"FASEB J"},{"issue":"4","key":"2019111723195598400_B62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1097-2765(01)00360-4","article-title":"Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi\/mi) mice.","volume":"8","author":"Weilbaecher","year":"2001","journal-title":"Mol Cell"},{"issue":"13","key":"2019111723195598400_B63","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.1074\/jbc.M111696200","article-title":"Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling.","volume":"277","author":"Mansky","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111723195598400_B64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng1194-256","article-title":"Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences.","volume":"8","author":"Steingrimsson","year":"1994","journal-title":"Nat Genet"},{"issue":"11","key":"2019111723195598400_B65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0168-9525(00)89143-X","article-title":"Insight into the microphthalmia gene.","volume":"11","author":"Moore","year":"1995","journal-title":"Trends Genet"},{"issue":"4","key":"2019111723195598400_B66","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S8756-3282(02)00672-5","article-title":"Osteoclastic acidification pathways during bone resorption.","volume":"30","author":"Rousselle","year":"2002","journal-title":"Bone"},{"issue":"9","key":"2019111723195598400_B67","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1073\/pnas.80.9.2752","article-title":"Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.","volume":"80","author":"Sly","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111723195598400_B68","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1073\/pnas.85.6.1962","article-title":"N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome.","volume":"85","author":"Lewis","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111723195598400_B69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00223-007-9098-x","article-title":"Phenotypic characteristics of bone in carbonic anhydrase II-deficient mice.","volume":"82","author":"Margolis","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2019111723195598400_B70","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1172\/JCI117235","article-title":"Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.","volume":"93","author":"Laitala","year":"1994","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111723195598400_B71","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/excr.1998.4071","article-title":"Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+.","volume":"242","author":"Lehenkari","year":"1998","journal-title":"Exp Cell Res"},{"issue":"38","key":"2019111723195598400_B72","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.176.4038.1031","article-title":"Carbonic anhydrase and bone remodeling: sulfonamide inhibition of bone resorption in organ culture.","volume":"176","author":"Minkin","year":"1972","journal-title":"Science"},{"issue":"1","key":"2019111723195598400_B73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/8756-3282(93)90256-A","article-title":"Effects of platelet-derived growth factor isoforms on calcium release from neonatal mouse calvariae.","volume":"14","author":"Cochran","year":"1993","journal-title":"Bone"},{"issue":"3","key":"2019111723195598400_B74","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1210\/endo.134.3.8119182","article-title":"Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts.","volume":"134","author":"Hock","year":"1994","journal-title":"Endocrinology"},{"issue":"1","key":"2019111723195598400_B75","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/bbrc.1998.9412","article-title":"Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor \u03b2.","volume":"251","author":"Zhang","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2019111723195598400_B76","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1210\/endo.136.12.7588297","article-title":"Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage.","volume":"136","author":"Franchimont","year":"1995","journal-title":"Endocrinology"},{"issue":"1","key":"2019111723195598400_B77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.V78.1.103.103","article-title":"Peptide growth factors stimulate macrophage colony-stimulating factor in murine stromal cells.","volume":"78","author":"Abboud","year":"1991","journal-title":"Blood"},{"issue":"3","key":"2019111723195598400_B78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptor\u03b2 by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"issue":"3","key":"2019111723195598400_B79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.leukres.2007.07.020","article-title":"Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines.","volume":"32","author":"Wihlidal","year":"2008","journal-title":"Leuk Res"},{"issue":"4","key":"2019111723195598400_B80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis.","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"issue":"3","key":"2019111723195598400_B81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/73542","article-title":"Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation.","volume":"24","author":"Li","year":"2000","journal-title":"Nat Genet"},{"issue":"1","key":"2019111723195598400_B82","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4049\/jimmunol.153.1.378","article-title":"IL-1 down-regulates platelet-derived growth factor-alpha receptor gene expression at the transcriptional level in human osteoblastic cells.","volume":"153","author":"Xie","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"2019111723195598400_B83","first-page":"83","article-title":"Evidence that a human osteosarcoma cell line which secretes a mitogen similar to platelet-derived growth factor requires growth factors present in platelet-poor plasma.","volume":"43","author":"Graves","year":"1983","journal-title":"Cancer Res"},{"issue":"4","key":"2019111723195598400_B84","first-page":"151","article-title":"Role of platelet derived growth factor in bone cell function.","volume":"2","author":"Canalis","year":"1992","journal-title":"Growth Regul"},{"issue":"5","key":"2019111723195598400_B85","doi-asserted-by":"crossref","first-page":"C1709","DOI":"10.1152\/ajpcell.1997.272.5.C1709","article-title":"Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures.","volume":"272","author":"Yu","year":"1997","journal-title":"Am J Physiol"},{"issue":"2","key":"2019111723195598400_B86","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1359\/jbmr.2002.17.2.257","article-title":"Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor.","volume":"17","author":"Kubota","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111723195598400_B87","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bone.2003.11.014","article-title":"Differential growth factor control of bone formation through osteoprogenitor differentiation.","volume":"34","author":"Chaudhary","year":"2004","journal-title":"Bone"},{"issue":"9","key":"2019111723195598400_B88","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1359\/jbmr.080409","article-title":"PDGF receptor beta is a potent regulator of mesenchymal stromal cell function.","volume":"23","author":"Tokunaga","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2019111723195598400_B89","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/978-3-540-47648-1_679","article-title":"Bone loss, cancer mediated.","volume-title":"Encyclopedia of Cancer","author":"Zannettino","year":"2009","edition":"ed 2"},{"issue":"10","key":"2019111723195598400_B90","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ncponc0320","article-title":"Clinical use of markers of bone turnover in metastatic bone disease.","volume":"2","author":"Seibel","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"issue":"3","key":"2019111723195598400_B91","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","article-title":"Bone metastases: pathophysiology and management policy.","volume":"9","author":"Nielsen","year":"1991","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111723195598400_B92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ijc.23903","article-title":"Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.","volume":"124","author":"Hiraga","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111723195598400_B93","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/1078-0432.306.11.1","article-title":"Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.","volume":"11","author":"Chelouche Lev","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111723195598400_B94","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jnci\/95.6.458","article-title":"Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.","volume":"95","author":"Uehara","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2019111723195598400_B95","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/0008-5472.CAN-03-3763","article-title":"Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.","volume":"64","author":"Kim","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"2019111723195598400_B96","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","article-title":"Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"2019111723195598400_B97","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/pros.20201","article-title":"In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.","volume":"63","author":"Kubler","year":"2005","journal-title":"Prostate"},{"issue":"1","key":"2019111723195598400_B98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1677\/erc.1.01307","article-title":"Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.","volume":"14","author":"Brama","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2019111723195598400_B99","first-page":"e68","article-title":"Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.","volume":"89","author":"Breccia","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"2019111723195598400_B100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pros.20130","article-title":"A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.","volume":"62","author":"Rao","year":"2005","journal-title":"Prostate"},{"issue":"4","key":"2019111723195598400_B101","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1464-410X.2006.06396.x","article-title":"A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.","volume":"98","author":"Lin","year":"2006","journal-title":"BJU Int"},{"issue":"1","key":"2019111723195598400_B102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2008.09.006","article-title":"Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.","volume":"181","author":"Mathew","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"2019111723195598400_B103","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2006.12.006","article-title":"Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.","volume":"69","author":"Bajaj","year":"2007","journal-title":"Urology"},{"issue":"2","key":"2019111723195598400_B104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-004-3974-0","article-title":"A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.","volume":"90","author":"Modi","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"2019111723195598400_B105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdn352","article-title":"Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-\u03b2: clinical activity and biological correlations.","volume":"19","author":"Cristofanilli","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111723195598400_B106","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.urology.2003.12.022","article-title":"Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.","volume":"63","author":"Tiffany","year":"2004","journal-title":"Urology"},{"issue":"19","key":"2019111723195598400_B107","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","article-title":"Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.","volume":"13","author":"Mathew","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111723195598400_B108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/8756-3282(93)90235-3","article-title":"Increased intracortical remodeling following fatigue damage.","volume":"14","author":"Mori","year":"1993","journal-title":"Bone"},{"issue":"3","key":"2019111723195598400_B109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S8756-3282(98)00104-5","article-title":"Intracortical remodeling in adult rat long bones after fatigue loading.","volume":"23","author":"Bentolila","year":"1998","journal-title":"Bone"},{"issue":"1","key":"2019111723195598400_B110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.1997.12.1.6","article-title":"Bone microdamage and skeletal fragility in osteoporotic and stress fractures.","volume":"12","author":"Burr","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019111723195598400_B111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"issue":"4","key":"2019111723195598400_B112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111723195598400_B113","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1359\/jbmr.2003.18.3.512","article-title":"Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.","volume":"18","author":"Komatsubara","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019111723195598400_B114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib.","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"issue":"9633","key":"2019111723195598400_B115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty.","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"2019111723195598400_B116","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib.","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2019111723195598400_B117","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2009.150","article-title":"Imatinib mesylate causes growth plate closure in vivo.","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111723195598400_B118","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/embo-reports\/kve094","article-title":"The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism.","volume":"2","author":"Labrador","year":"2001","journal-title":"EMBO Rep"},{"issue":"5","key":"2019111723195598400_B119","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1359\/jbmr.090225","article-title":"Role of the osteoblast lineage in the bone marrow hematopoietic niches.","volume":"24","author":"Wu","year":"2009","journal-title":"J Bone Miner Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/4\/766\/1458512\/zh800410000766.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/4\/766\/1458512\/zh800410000766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:19:42Z","timestamp":1739413182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/115\/4\/766\/26767\/Dysregulation-of-bone-remodeling-by-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,28]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-08-237404","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,28]]}}}